Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 4/20 | 0.34 |
| ▸ | MMP3 | P08254 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18272869 | 0.84 | MAPT (0.41) | MAPTHDAC2MMP2MMP3ECE1 | |
| SCHEMBL25634004 | 0.84 | MAPT (0.41) | MAPTHDAC2MMP2MMP3ECE1 | |
| SCHEMBL19776046 | 0.84 | MAPT (0.41) | MAPTHDAC2MMP2MMP3ECE1 | |
| SCHEMBL20349752 | 0.80 | ALDH1A1 (0.36) | MAPTHDAC2MMP2MMP3POLB | |
| SCHEMBL12040121 | 0.75 | CA1 (0.42) | HDAC2MMP2MMP3POLB | |
| SCHEMBL12040054 | 0.75 | CA1 (0.42) | HDAC2MMP2MMP3POLB | |
| SCHEMBL13186075 | 0.74 | POLB (0.33) | HDAC2MMP2MMP3POLB | |
| SCHEMBL8277450 | 0.74 | MAPT (0.46) | MAPTHDAC2MMP2POLB | |
| SCHEMBL13385188 | 0.74 | MAPT (0.46) | MAPTHDAC2MMP2POLB | |
| SCHEMBL13435004 | 0.73 | MMP1 (0.35) | HDAC2MMP2MMP3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144504-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144504-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | MAPT 3296/4885HDAC2 3446/4885MMP2 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.